Lionel Carnot, MS, MBA, is a Managing Director of Bay City Capital and has been extensively involved in the firm's activities since he joined The Pritzker Organization in 2000. He manages the firm's investments in Europe. Prior to The Pritzker Organization, Mr. Carnot was a Principal at Oracle Partners, a healthcare hedge fund. He also held several positions in the pharmaceutical industry, including Product Manager for Prozac at Eli Lilly as well as several sales and marketing positions at Aventis. Mr. Carnot was also a strategy and management consultant to the biopharmaceutical industry while at Booz Allen & Hamilton and Accenture Strategic Services. Mr. Carnot is a member of the board of directors of Interleukin Genetics, Merus B.V., Madrigal Pharmaceuticals, and Tallikut Pharmaceuticals, and is a former member of the board of Reliant Pharmaceuticals, Pathway Diagnostics, BioSeek, and Nexus Dx. Mr. Carnot holds an MBA with Distinction from INSEAD and an MS with honors in Molecular Biology from the University of Geneva.